

UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE

In re: Akorn, Inc., et al.,

Debtor(s)

§  
§  
§  
§

Case No. 20-11177

Lead Case No. 20-11177

☒ Jointly Administered

**Post-confirmation Report**

Chapter 11

Quarter Ending Date: 12/31/2022

Petition Date: 05/20/2020

Plan Confirmed Date: 09/04/2020

Plan Effective Date: 10/01/2020

This Post-confirmation Report relates to: ☒ Reorganized Debtor

☐ Other Authorized Party or Entity:

Name of Authorized Party or Entity

/s/ Amanda R. Steele

Signature of Responsible Party

01/17/2023

Date

Amanda R. Steele

Printed Name of Responsible Party

Richards, Layton & Finger, P.A.  
One Rodney Square, 920 N. King Street  
Wilmington, DE 19801

Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.



201117723011700000000001

Debtor's Name Akorn, Inc., et al.,

Case No. 20-11177

**Part 1: Summary of Post-confirmation Transfers**

	Current Quarter	Total Since Effective Date
a. Total cash disbursements	\$4,712,630	\$11,534,276
b. Non-cash securities transferred	\$0	\$0
c. Other non-cash property transferred	\$0	\$0
d. Total transferred (a+b+c)	\$4,712,630	\$11,534,276

**Part 2: Preconfirmation Professional Fees and Expenses**

a.			Approved Current Quarter	Approved Cumulative	Paid Current Quarter	Paid Cumulative	
	Professional fees & expenses (bankruptcy) incurred by or on behalf of the debtor <i>Aggregate Total</i>		\$0	\$19,437,319	\$0	\$19,437,319	
	<i>Itemized Breakdown by Firm</i>						
		Firm Name	Role				
	i	Kurtzman Carson Consultants L	Other	\$0	\$112,549	\$0	\$112,549
	ii	AlixPartners, LLP	Financial Professional	\$0	\$1,754,654	\$0	\$1,754,654
	iii	Kirkland & Ellis LLP and Kirk	Lead Counsel	\$0	\$5,781,124	\$0	\$5,781,124
	iv	Richards, Layton & Finger, P.A	Co-Counsel	\$0	\$422,773	\$0	\$422,773
	v	PJT Partners LP	Financial Professional	\$0	\$11,366,219	\$0	\$11,366,219
	vi						
	vii						
	viii						
	ix						
	x						
	xi						
	xii						
	xiii						
	xiv						
	xv						
	xvi						
	xvii						
	xviii						
	xix						
	xx						
	xxi						
	xxii						
	xxiii						
	xxiv						
	xxv						
xxvi							
xxvii							
xxviii							
xxix							

Debtor's Name Akorn, Inc., et al.,

Case No. 20-11177

xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						
xxxvii						
xxxviii						
xxxix						
xl						
xli						
xl ii						
xl iii						
xl iv						
xl v						
xl vi						
xl vii						
xl viii						
xl ix						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						

Debtor's Name Akorn, Inc., et al.,

Case No. 20-11177

lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						
lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						
xc						
xcii						
xciii						
xciv						
xcv						
xcvi						
xcvii						
xcviii						
xcix						
c						
ci						

b.			Approved Current Quarter	Approved Cumulative	Paid Current Quarter	Paid Cumulative
	Professional fees & expenses (nonbankruptcy) incurred by or on behalf of the debtor		\$0	\$1,482,291	\$0	\$1,482,291
	<i>Aggregate Total</i>					
	<i>Itemized Breakdown by Firm</i>					
	Firm Name	Role				
i	PricewaterhouseCoopers	Financial Professional	\$0	\$800,000	\$0	\$800,000
ii	Grant Thornton LLP	Financial Professional	\$0	\$682,291	\$0	\$682,291
iii						
iv						
v						
vi						

Debtor's Name Akorn, Inc., et al.,

Case No. 20-11177

	vii					
	viii					
	ix					
	x					
	xi					
	xii					
	xiii					
	xiv					
	xv					
	xvi					
	xvii					
	xviii					
	xix					
	xx					
	xxi					
	xxii					
	xxiii					
	xxiv					
	xxv					
	xxvi					
	xxvii					
	xxviii					
	xxix					
	xxx					
	xxxi					
	xxxii					
	xxxiii					
	xxxiv					
	xxxv					
	xxxvi					
	xxxvii					
	xxxviii					
	xxxix					
	xl					
	xli					
	xlii					
	xliii					
	xliv					
	xlv					
	xlvi					
	xlvii					
	xlviii					

Debtor's Name Akorn, Inc., et al.,

Case No. 20-11177

xlix						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						
lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						

Debtor's Name Akorn, Inc., et al.,

Case No. 20-11177

	xc						
	xcii						
	xciii						
	xciv						
	xcv						
	xcvi						
	xcvii						
	xcviii						
	xcix						
	c						
	ci						
c.	All professional fees and expenses (debtor & committees)			\$0	\$22,880,299	\$0	\$22,880,299

**Part 3: Recoveries of the Holders of Claims and Interests under Confirmed Plan**

	Total Anticipated Payments Under Plan	Paid Current Quarter	Paid Cumulative	Allowed Claims	% Paid of Allowed Claims
a. Administrative claims	\$0	\$0	\$0	\$0	0%
b. Secured claims	\$166,414	\$66,414	\$166,414	\$166,414	100%
c. Priority claims	\$4,304,640	\$4,299,640	\$4,304,640	\$4,304,640	100%
d. General unsecured claims	\$0	\$0	\$0	\$0	0%
e. Equity interests	\$0	\$0	\$0		

**Part 4: Questionnaire**a. Is this a final report? Yes ☐ No ☒

If yes, give date Final Decree was entered: \_\_\_\_\_

If no, give date when the application for Final Decree is anticipated: \_\_\_\_\_

b. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes ☒ No ☐

Debtor's Name Akorn, Inc., et al.,

Case No. 20-11177

**Privacy Act Statement**

28 U.S.C. § 589b authorizes the collection of this information and provision of this information is mandatory. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6) and to otherwise evaluate whether a reorganized chapter 11 debtor is performing as anticipated under a confirmed plan. Disclosure of this information may be to a bankruptcy trustee when the information is needed to perform the trustee's duties, or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." *See* 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: [http://www.justice.gov/ust/eo/rules\\_regulations/index.htm](http://www.justice.gov/ust/eo/rules_regulations/index.htm). Failure to provide this information could result in the dismissal or conversion of your bankruptcy case, or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

**I declare under penalty of perjury that the foregoing Post-confirmation Report and its attachments, if any, are true and correct and that I have been authorized to sign this report.**

/s/ Tim Daileader

Signature of Responsible Party

Authorized Signatory

Title

Tim Daileader

Printed Name of Responsible Party


01/17/2023

Date




Debtor's Name Akorn, Inc., et al.,


Case No. 20-11177




Page 1



Other Page 1




Page 2 Minus Tables




Bankruptcy Table 1-50

Debtor's Name Akorn, Inc., et al.,


Case No. 20-11177




Bankruptcy Table 51-100



Non-Bankruptcy Table 1-50



Non-Bankruptcy Table 51-100



Part 3, Part 4, Last Page

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE DISTRICT OF DELAWARE**

---

In re:

AKORN, INC.,

Debtor.<sup>1</sup>

---

)  
) Chapter 11  
)  
) Case No. 20-11177 (KBO)  
)  
)  
)  
)

**GLOBAL NOTES AND STATEMENT OF LIMITATIONS,  
METHODOLOGY AND DISCLAIMERS REGARDING  
POST-CONFIRMATION QUARTERLY REPORT**

Akorn, Inc. (“Akorn” or the “Debtor”) has filed the attached post-confirmation quarterly report (the “PCR”) in the United States Bankruptcy Court for the District of Delaware (the “Court”). Drivetrain, LLC, the Plan Administrator (as defined in the *Modified Joint Chapter 11 Plan of Akorn, Inc. and Its Debtor Affiliates* (the “Plan”))<sup>2</sup> and sole representative of the Debtors, prepared the PCR with the assistance of its advisors and professionals solely for the purpose of complying with the quarterly reporting requirements applicable in the chapter 11 cases and is in a format acceptable to the U.S. Trustee. The financial information contained herein is unaudited, limited in scope, and is not prepared in accordance with accounting principles generally accepted in the United States of America nor in accordance with federal or state securities laws or other applicable non-bankruptcy law or in lieu of complying with any periodic reporting requirements thereunder.

In preparing the PCR, the Plan Administrator relied on financial data available from the limited books and records available to it at the time of such preparation, as well certain filings from the docket in the Debtors’ chapter 11 cases. Although the Plan Administrator made commercially reasonable efforts to ensure the accuracy and completeness of the PCR, inadvertent errors or omissions may exist.<sup>3</sup> For the avoidance of doubt, the Debtor and Plan Administrator hereby reserve their rights to amend and supplement the PCR as may be necessary or appropriate.

---

<sup>1</sup> The Debtor in this chapter 11 case, along with the last four digits of the Debtor’s federal tax identification number, is: Akorn, Inc. (7400). The Chapter 11 Cases of the following entities (collectively, the “Former Debtors” and, together with Akorn, the “Debtors”), formerly administratively consolidated with the foregoing case, have been closed: 10 Edison Street LLC (7890); 13 Edison Street LLC; Advanced Vision Research, Inc. (9046); Akorn (New Jersey), Inc. (1474); Akorn Animal Health, Inc. (6645); Akorn Ophthalmics, Inc. (6266); Akorn Sales, Inc. (7866); Clover Pharmaceuticals Corp. (3735); Covenant Pharma, Inc. (0115); Hi-Tech Pharmacal Co., Inc. (8720); Inspire Pharmaceuticals, Inc. (9022); Oak Pharmaceuticals, Inc. (6647); Olta Pharmaceuticals Corp. (3621); VersaPharm Incorporated (6739); VPI Holdings Corp. (6716); and VPI Holdings Sub, LLC. The location of the Debtor’s service address is: 1925 W. Field Court, Suite 300, Lake Forest, Illinois 60045

<sup>2</sup> Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Plan.

<sup>3</sup> While commercially reasonable efforts have been made to provide accurate and complete information in the PCR, inadvertent errors or omissions may exist. The Debtor and Plan Administrator, and their agents, advisors,

Each signatory to the PCR has necessarily relied upon the efforts, statements, advice, and representations of personnel of the Debtors and the Debtors' advisors and professionals. Each signatory has not (and could not have) personally verified the accuracy of each such statement, representation, and answer contained in the PCR.

**Part 1: Summary of Post-confirmation Transfers.** The amounts identified in Part 1 of the PCR (*Summary of Post-confirmation Transfers*) have been derived from the limited books and records available to the Plan Administrator at the time of the preparation of the PCR and are on account of authorized disbursements and distributions made pursuant to the Plan. A Holder of a Claim may have been paid, in whole or in part, on account of such Claim by a party that is not the Debtor as contemplated by the Plan. The signatories to the PCR are not aware of any such payments and are not in possession of records that could confirm any such payments.

**Part 2: Preconfirmation Professional Fees and Expenses.** The amounts identified in Part 2 of the PCR (*Preconfirmation Professional Fees and Expenses*) have been derived solely from orders [Docket Nos. 765, 879, 890 & 891] entered in the Debtors' chapter 11 cases allowing and authorizing payment of certain professionals' fees and expenses as set forth therein. Prior to the date of entry of the order confirming the Plan, other professional fees or expenses may have been incurred and/or paid. The signatories to the PCR are not aware of any such fees or expenses and are not in possession of records that could confirm any such fees or expenses. Payments made to professionals utilized in the ordinary course of the Debtors' business pursuant the Bankruptcy Court's order [Docket No. 222] are not included in Part 2 of the PCR. Reference is made to the *Notice of Filing of Debtors' First Quarterly Statement Regarding Payments Made to Ordinary Course Professionals for Services Provided During the Period of May 20, 2020 Through July 31, 2020* [Docket No. 640] for such payment detail.

**Part 3: Recoveries of the Holders of Claims and Interests under Confirmed Plan.** Efforts to review and reconcile Claims and Interests filed, scheduled, or otherwise asserted in the chapter 11 cases remain ongoing. Accordingly, the Plan Administrator is not able to anticipate or determine at this time total payments that may be made under the Plan nor the total Claims and Interests that may be Allowed under the Plan. Therefore, "\$0" or "0%" has been entered in certain lines of Part 3 of the PCR (*Recoveries of the Holders of Claims and Interests Under Confirmed Plan*) where such information is unknown, not yet determined, or otherwise not applicable, including instances where the Plan does not provide for or contemplate recoveries to certain Classes of Claims or Interests.

**Part 4: Questionnaire.** The Plan Administrator cannot currently anticipate, with any degree of certainty, when the application for a Final Decree closing the chapter 11 case of Akorn may be filed.

---

attorneys, and other professionals, as applicable, do not guarantee or warrant the accuracy or completeness of the data that is provided in the PCR.